I reported previously (Oct 2014) that the Aramchol treatment from Israel’s Galmed for Non-Alcoholic Steatohepatitis (NASH) had been fast-tracked by the US FDA. Latest trials show that twice-daily dosages of Aramchol significantly increased blood plasma levels.

http://galmedpharma.investorroom.com/2019-03-12-Galmed-Reports-Positive-Results-From-Pharmacokinetic-Split-Dose-Study-of-Aramchol